SEC 13FLatest Quarter: 2026 Q3·Holdings as of 2026-09-30·~1.6 months lag (50 days)
2026 Q3 Received: 30 / 33 (3 not filed)
MRNA生命科学与高端医疗● Live Quotes Active

Moderna, Inc.

No mega hedge funds in our coverage currently report a major 13F position in this stock for 2026 Q3

Live Price
24h Change
Mega Funds Holding
0/ 33 funds

Coverage: 0.0%

Avg Portfolio Weight
0%

-

Net Buying Funds Ratio
0%Net Buying
+0/0/-0

💡 Methodology: Share changes > ±0.5% are classified as Buys/Sells; changes within ±0.5% are Unchanged. Net Buying Ratio = (Buy + New) / Total Holding Funds.

Total Tracked Shares
0shares

Based on 2026 Q3 SEC 13F filings

SGDC Dual-Core EngineSuper-Growth Dual-Core Radar

🚀MRNA SGDC Quant Rating & Setup

Open SGDC Screener↗
4P Grade
C Tier(61 pts)
RS Rating
75/ 99
Pattern Setup
Base Setup
Pivot Benchmark
$280.80Breakdown · No Support

📌 Business Moat Summary:Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

ℹ️
Resonance Status:Not in Current Resonance PoolMom: 68.0Momentum: 2026-11-18 close

As of 2026-11-18 close, trading below 50SMA support (settlement price $196.79 < $205.61), triggering momentum risk gate.

View 2 Double Resonance Leaders→
ℹ️
13F Hedge Fund Coverage NoticeNone of the 33 tracked mega hedge funds (e.g., Berkshire Hathaway, Bridgewater, Renaissance, Citadel) currently report a major 13F position in MRNA.✦ Note: This stock is actively tracked by the SGDC Super-Growth Quant Engine (4P Grade C, RS Rating 75).

📈8-Quarter Institutional Ownership Evolution

Historical trajectory of institutional holders and allocation weight across the last 8 quarters

Select Quarter:
0% avg
0 funds2026 Q3
0% avg
0 funds2026 Q2
0% avg
0 funds2026 Q1
0% avg
0 funds2025 Q4
0% avg
0 funds2025 Q3
0% avg
0 funds2025 Q2
0% avg
0 funds2025 Q1
0% avg
0 funds2024 Q4
0% avg
0 funds2024 Q3
2026 Q3|Report Date: 2026-09-30
Holding Funds: 0 fundsTotal Shares: 0Avg Weight: 0%

🏛️Institutional Investors Holding this Stock2026 Q3

Examine each hedge fund holding this ticker in 2026 Q3, weight, shares, and action

Sort by:
Manager / FundFund AUMWeightShares HeldActionAction
No tracked mega hedge funds currently hold this stock.
🎯

Want to see Wall Street's Top 50 Consensus Buys?

Instead of checking individual stocks, get the complete list of high-conviction overlap picks across 33 hedge funds.

Go to Consensus Screener →

⚡Planning to trade MRNA?

Add this symbol to your private journal or dividend tracker to monitor institutional moves.